Literature DB >> 9559779

Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.

S Walker1, S A Tailor, M Lee, L Louie, M Louie, A E Simor.   

Abstract

Newer formulations of amphotericin B (AmB) complexed with liposomes or lipid suspensions have been developed. Preliminary studies have suggested that AmB in Intralipid (IL) may be as effective as, but less toxic than, conventional formulations of AmB, but few data are available regarding its stability, compatibility, or in vitro antifungal activity. A compatibility study was done to evaluate the effects of AmB concentrations in IL containing either 10 or 20% soybean oil. The effects of temperature, shaking, and AmB and IL concentrations on the stability of AmB-IL suspensions were analyzed by visual inspection and liquid chromatography. The in vitro antifungal activity of AmB-IL, compared to that of AmB alone against reference strains of Candida species was determined by using a broth macrodilution method in accordance with National Committee for Clinical Laboratory Standards guidelines (M27-T). Samples of AmB-IL which were lightly shaken retained more than 90% of the AmB concentration over 21 days when stored at either 4 or 23 degrees C. Varying the AmB concentration did not appear to affect the stability of AmB-IL. However, a precipitate was formed when mixtures with more than 30% lipid as a proportion of the total volume were centrifuged. AmB-IL and AmB alone had similar in vitro antifungal activities against reference strains of yeasts. Further pharmacologic and clinical studies with AmB-IL are warranted, although AmB should not be combined with IL in concentrations capable of producing a precipitate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559779      PMCID: PMC105538          DOI: 10.1128/AAC.42.4.762

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Amphotericin B does not mix with fat emulsion.

Authors:  L A Trissel
Journal:  Am J Health Syst Pharm       Date:  1995-07-01       Impact factor: 2.637

2.  Precipitation of amphotericin B from i.v. fat emulsion.

Authors:  P E Heide
Journal:  Am J Health Syst Pharm       Date:  1997-06-15       Impact factor: 2.637

Review 3.  Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.

Authors:  V J Wiebe; M W DeGregorio
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec

4.  Stability of amphotericin B in 5% dextrose injection stored at 4 or 25 degrees C for 120 hours.

Authors:  M D Lee; M M Hess; B A Boucher; A M Apple
Journal:  Am J Hosp Pharm       Date:  1994-02-01

5.  Serum pharmacology of amphotericin B applied in lipid emulsions.

Authors:  V Heinemann; B Kähny; U Jehn; D Mühlbayer; A Debus; K Wachholz; D Bosse; H J Kolb; W Wilmanns
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.

Authors:  R Kirsh; R Goldstein; J Tarloff; D Parris; J Hook; N Hanna; P Bugelski; G Poste
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

Review 7.  Clinical use of liposomal and lipid-complexed amphotericin B.

Authors:  S de Marie; R Janknegt; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

8.  A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.

Authors:  D Caillot; G Reny; E Solary; O Casasnovas; P Chavanet; B Bonnotte; L Perello; M Dumas; F Entezam; H Guy
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

9.  Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers.

Authors:  V L Kan; J E Bennett; M A Amantea; M C Smolskis; E McManus; D M Grasela; J W Sherman
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

10.  [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].

Authors:  P Chavanet; N Charlier; A Brenet; A Goux; E Muggéo; D Caillot; O Casasnovas; J P Kistermann; A Waldner; H Portier
Journal:  Pathol Biol (Paris)       Date:  1992-05
View more
  3 in total

Review 1.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 2.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

3.  Effects of Solvents, Emulsions, Cosolvents, and Complexions on Ex Vivo Mouse Myometrial Contractility.

Authors:  Christopher J Hansen; Shajila Siricilla; Naoko Boatwright; Jackson H Rogers; Melissa E Kumi; Jennifer Herington
Journal:  Reprod Sci       Date:  2021-04-14       Impact factor: 3.060

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.